Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/3629
Title: Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases
Authors: Decara, Juan
Rivera, Patricia
López-Gambero, Antonio Jesús
Serrano, Antonia
Pavón, Francisco Javier
Baixeras, Elena
Rodríguez de Fonseca, Fernando
Suárez, Juan
metadata.dc.contributor.authoraffiliation: [Decara,J; López-Gambero,AJ; Serrano,A; Pavón,FJ; Rodríguez de Fonseca,F; Suárez,J] UGC Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, Spain. [Rivera,P] Departamento de Endocrinología, Fundación Investigación Biomédica del Hospital Infantil Universitario Niño Jesús, Madrid, Spain. [Pavón,FJ] Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV) and UGC del Corazón, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain. [Baixeras,E] Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Málaga, IBIMA, Málaga, Spain.
Keywords: PPARa;PPARg;PPARb/d;Inflammatory bowel diseases;Ulcerative colitis;Crohn's disease;Receptores activados del proliferador del peroxisoma;Enfermedades inflamatorias del intestino;Colitis ulcerosa;Enfermedad de Crohn
metadata.dc.subject.mesh: Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Receptors, Cytoplasmic and Nuclear::Peroxisome Proliferator-Activated Receptors
Medical Subject Headings::Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases
Medical Subject Headings::Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases::Colitis, Ulcerative
Medical Subject Headings::Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases::Crohn Disease
Medical Subject Headings::Phenomena and Processes::Metabolic Phenomena::Metabolism::Lipid Metabolism
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Specialty Uses of Chemicals::Laboratory Chemicals::Ligands
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Transcription Factors::NF-kappa B
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Transcription Factors::Receptors, Cytoplasmic and Nuclear::Peroxisome Proliferator-Activated Receptors::PPAR gamma
Medical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Inflammatory Agents
Medical Subject Headings::Phenomena and Processes::Physiological Phenomena::Physiological Processes::Homeostasis
Medical Subject Headings::Chemicals and Drugs::Pharmaceutical Preparations
Issue Date: 27-May-2020
Publisher: Frontiers
Citation: Decara J, Rivera P, López-Gambero AJ, Serrano A, Pavón FJ, Baixeras E, et al. Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases. Front Pharmacol. 2020 May 27;11:730
Abstract: The peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor proteins that promote ligand-dependent transcription of target genes that regulate energy production, lipid metabolism, and inflammation. The PPAR superfamily comprises three subtypes, PPARα, PPARγ, and PPARβ/δ, with differential tissue distributions. In addition to their different roles in the regulation of energy balance and carbohydrate and lipid metabolism, an emerging function of PPARs includes normal homeostasis of intestinal tissue. PPARα activation represses NF-κB signaling, which decreases the inflammatory cytokine production by different cell types, while PPARγ ligands can inhibit activation of macrophages and the production of inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, and Il-1β. In this regard, the anti-inflammatory responses induced by PPAR activation might restore physiopathological imbalances associated with inflammatory bowel diseases (IBD). Thus, PPARs and their ligands have important therapeutic potential. This review briefly discusses the roles of PPARs in the physiopathology and therapies of the most important IBDs, ulcerative colitis (UC), and Crohn's disease (CD), as well some new experimental compounds with PPAR activity as promising drugs for IBD treatment.
URI: http://hdl.handle.net/10668/3629
metadata.dc.relation.publisherversion: https://www.frontiersin.org/articles/10.3389/fphar.2020.00730/full
metadata.dc.identifier.doi: 10.3389/fphar.2020.00730
ISSN: 1663-9812 (Online)
Appears in Collections:01- Artículos - Hospital Virgen de la Victoria
01- Artículos - IBIMA. Instituto de Investigación Biomédica de Málaga

Files in This Item:
File Description SizeFormat 
Decara_PeroxisomeProliferator.pdfRevisión2,22 MBAdobe PDFView/Open


This item is protected by original copyright



This item is licensed under a Creative Commons License Creative Commons